MST access valued PAR at $4.25 in August 2021 with the expectation of IND approval in October, which actually occurred in November. The report is available at https://paradigmbiopharma.com/wp-content/uploads/2021/08/MST-Access-PAR-Update-Report-4Aug212.pdf " ASX-listed biotechnology company,Paradigm Biopharma’s(PAR.AX)strategy is to take already approved medicines that have shown safety and efficacy in one condition and repurpose them for new indications. The aim is to reduce time, cost and risk. Its first candidate is injectable pentosan polysulphatesodium (iPPS), Zilosul®, for use in osteoarthritis in the knee (KOA) and hip (HOA), and mucopolysaccharidosis (MPS), a genetic enzyme disease. Management presents a strong background in drug development. "
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)